99 related articles for article (PubMed ID: 25022554)
1. HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma.
Kalogiannidis I; Petousis S; Bobos M; Margioula-Siarkou C; Topalidou M; Papanikolaou A; Vergote I; Agorastos T
Arch Gynecol Obstet; 2014 Dec; 290(6):1231-7. PubMed ID: 25022554
[TBL] [Abstract][Full Text] [Related]
2. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
3. [Clinical application of adult comorbidity evaluation-27 in endometrial cancer].
Tian WY; Wang YM; Yan Y; Gao JP; Sun DD; Jiang S; Sheng Y; Teng F; Xue FX
Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):810-817. PubMed ID: 27916063
[No Abstract] [Full Text] [Related]
4. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
[TBL] [Abstract][Full Text] [Related]
5. Metabolic syndrome is an independent prognostic factor for endometrial adenocarcinoma.
Ni J; Zhu T; Zhao L; Che F; Chen Y; Shou H; Yu A
Clin Transl Oncol; 2015 Oct; 17(10):835-9. PubMed ID: 26260911
[TBL] [Abstract][Full Text] [Related]
6. Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification.
Werner HM; Trovik J; Marcickiewicz J; Tingulstad S; Staff AC; Amant F; Salvesen HB;
Gynecol Oncol; 2012 Apr; 125(1):103-8. PubMed ID: 22100838
[TBL] [Abstract][Full Text] [Related]
7. [The value of Ki-67 antigen expression in tissue microarray method in prediction prognosis of patients with endometrioid endometrial cancer].
Gottwald L; Kubiak R; Sek P; Piekarski J; Szwalski J; Pasz-Walczak G; Spych M; Suzin J; Tylińskis W; Jeziorski A
Ginekol Pol; 2013 Jun; 84(6):444-9. PubMed ID: 24032262
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray.
Ismail HM; Moneer M; El-Baradie M; Khorshid O; Touny A
J Egypt Natl Canc Inst; 2007 Jun; 19(2):147-57. PubMed ID: 19034345
[TBL] [Abstract][Full Text] [Related]
9. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
10. Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.
Jongen VH; Briët JM; de Jong RA; Joppe E; ten Hoor KA; Boezen HM; Evans DB; Hollema H; van der Zee AG; Nijman HW
Int J Gynecol Cancer; 2009 May; 19(4):670-6. PubMed ID: 19509570
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
[TBL] [Abstract][Full Text] [Related]
12. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey.
Lajer H; Elnegaard S; Christensen RD; Ortoft G; Schledermann DE; Mogensen O
Acta Obstet Gynecol Scand; 2012 Aug; 91(8):976-82. PubMed ID: 22548255
[TBL] [Abstract][Full Text] [Related]
13. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
14. Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view.
Foerster R; Kluck R; Arians N; Rieken S; Rief H; Adeberg S; Bostel T; Schlampp I; Debus J; Lindel K
Radiat Oncol; 2015 Jul; 10():147. PubMed ID: 26179059
[TBL] [Abstract][Full Text] [Related]
15. Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression.
Nazeer T; Ballouk F; Malfetano JH; Figge H; Ambros RA
Am J Obstet Gynecol; 1995 Dec; 173(6):1829-34. PubMed ID: 8610771
[TBL] [Abstract][Full Text] [Related]
16. [Significance of prognostic evaluation of International Federation of Gynecology and Obstetrics 2009 staging system on stage I endometrioid adenocarcinoma].
Wang ZQ; Zhang Y; Wang JL; Shen DH; Mu T; Zhao X; Yao YY; Bai Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Jan; 47(1):33-9. PubMed ID: 22455691
[TBL] [Abstract][Full Text] [Related]
17. Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients.
Binder PS; Peipert JF; Kallogjeri D; Brooks RA; Massad LS; Mutch DG; Powell MA; Thaker PH; McCourt CK
Am J Obstet Gynecol; 2016 Dec; 215(6):766.e1-766.e9. PubMed ID: 27457116
[TBL] [Abstract][Full Text] [Related]
18. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.
Lukes AS; Kohler MF; Pieper CF; Kerns BJ; Bentley R; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC; Berchuck A
Cancer; 1994 May; 73(9):2380-5. PubMed ID: 7909491
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of age in surgically staged patients with Type II endometrial carcinoma.
Vance S; Yechieli R; Cogan C; Hanna R; Munkarah A; Elshaikh MA
Gynecol Oncol; 2012 Jul; 126(1):16-9. PubMed ID: 22507535
[TBL] [Abstract][Full Text] [Related]
20. Expression of PTEN and β-Catenin and Their Relationship With Clinicopathological and Prognostic Factors in Endometrioid Type Endometrial Cancer.
Sal V; Demirkiran F; Erenel H; Tokgozoglu N; Kahramanoglu I; Bese T; Turan H; Sofiyeva N; Calay Z; Arvas M; Guralp O
Int J Gynecol Cancer; 2016 Mar; 26(3):512-20. PubMed ID: 26894937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
